Bloomberg -- Orexigen Therapeutics Inc.’s new diet pill Contrave has unclear benefits, according to U.S. regulators deciding whether to approve the nation’s first prescription drug for obesity in more than a decade. Contrave satisfied only one of two recommended measures of effectiveness in studies reviewed in a Food and Drug Administration staff report released today.
